GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Onconetix Inc (NAS:ONCO) » Definitions » Cash per Share

ONCO (Onconetix) Cash per Share : $0.04 (As of Sep. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Onconetix Cash per Share?

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Onconetix's Cash per Share for the quarter that ended in Sep. 2024 was $0.04.

Onconetix Cash per Share Historical Data

The historical data trend for Onconetix's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Onconetix Cash per Share Chart

Onconetix Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Cash per Share
21.92 15.61 7.06 67.42 8.16

Onconetix Quarterly Data
Dec19 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.20 8.16 8.00 1.67 0.04

Onconetix Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Onconetix's Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=4.554/0.56
=8.16

Onconetix's Cash per Share for the quarter that ended in Sep. 2024 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=0.341/8.31
=0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Onconetix  (NAS:ONCO) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Onconetix Cash per Share Related Terms

Thank you for viewing the detailed overview of Onconetix's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Onconetix Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Onconetix Inc (NAS:ONCO) » Definitions » Cash per Share
Comparable Companies
BPTH VINC EMMA NAYA SLRX WINT ZVSA TSOI NBIO EVFM VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
201 East Fifth Street, Suite 1900, Cincinnati, OH, USA, 45202
Website
https://www.onconetix.com
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.
Executives
Neil J Campbell director, officer: Chief Executive Officer 225 CHIMNEY CORNER LANE, SUITE 2001, JUPITER FL 33458
Bruce Harmon officer: Chief Financial Officer 316 DEL PRADO BLVD. S., SUITE 204, CAPE CORAL FL 33990
Timothy R. Ramdeen director 201 E. FIFTH STREET SUITE 1900, CINCINNATI OH 45202
Vuk Jeremic director BLUE WATER VACCINES INC., 201 E. FIFTH STREET, SUITE 1900, CINCINNATI OH 45202
Cincinnati Cornerstone Investors Bwv I, Llc 10 percent owner 2900 READING ROAD, SUITE 410, CINCINNATI OH 45206
Cincinnati Cornerstone Capital Llc other: Manager-Cinti Cornerstone Inv. 2900 READING RD, SUITE 410, CINCINNATI OH 45206
Joseph Hernandez 10 percent owner, officer: CEO C/O MICROLIN BIO, INC., NEW YORK NY 10022
Simon Tarsh director 201 E. FIFTH STREET SUITE 1900, CINCINNATI OH 45202
Allan Shaw director C/O CELSUS THERAPEUTICS PLC, 24 WEST 40TH STREET, NEW YORK NY 10018
Erin Henderson officer: Chief Business Officer 201 E. FIFTH STREET, SUITE 1900, CINCINNATI OH 45202
James Sapirstein director 1517 SAN JACINTO, HOUSTON TX 77002
Kimberly M Murphy director 101 EAST KENNEDY BLVD., SUITE 2800, TAMPA FL 33602
Rice John Mccune Jr. director 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Jon Garfield officer: CFO 11111 SANTA MONICA BLVD., SUITE 650, LOS ANGELES CA 90025
Michael Venerable director 201 E. FIFTH STREET, SUITE 1900, CINCINNATI OH 45202